Latest Healthcare News

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.

Oceania Healthcare has posted a strong half-year turnaround with improved sales, cost savings, and reduced gearing, setting the stage for renewed growth and operational strength.

Oceania Healthcare reported a slight dip in revenue but impressive gains in profitability for the first half of 2025, highlighting operational resilience amid a challenging environment.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

Monash IVF Group reported a 6.7% revenue increase to $271.9 million for FY25, alongside an 8.1% decline in underlying NPAT, aligning with prior guidance. The company outlined a cautious FY26 outlook focused on innovation, doctor retention, and cost management.

Monash IVF Group reported solid FY25 revenue and EBITDA growth despite sector softness and clinical incidents, while announcing a leadership transition and dividend pause.

Emyria Limited is fast-tracking its national rollout of Empax mental health clinics, backed by a strong $8 million institutional placement and new dual-payer funding pathways.

HITIQ Limited has launched its PROTEQT™ concussion management system in North America, securing exclusive Canadian distribution rights and initiating a dual-channel market strategy targeting hockey’s vast ecosystem.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

ReNerve Limited has raised $3.2 million through a two-tranche share placement to accelerate its sales and marketing efforts in the US and support upcoming product launches, including a new nerve conduit range.

Cann Group Limited has successfully raised an additional $2.5 million through a Share Purchase Plan and shortfall placement, complementing a prior $6.5 million institutional placement. These funds will primarily support debt repayment and strengthen the company’s financial position.

HeraMED has achieved a significant regulatory milestone with the Therapeutic Goods Administration upgrading its HeraBEAT fetal heart rate monitor to Class IIb, making it the only remote home-use device approved in Australia. This positions the company for a potentially lucrative expansion in the Australian maternity care market.